Cardinal Health 108, LLC

Cardinal Health 108, LLC, doing business as Metro Medical Supply, is a Dublin, Ohio-based for-profit limited liability company and subsidiary of Cardinal Health, Inc. that supplies specialized pharmaceutical products and medical supplies to federal healthcare agencies as a prime contractor, competing exclusively through full-and-open procurement on an unrestricted basis with no set-aside designations across all recent awards.

The vendor's federal footprint centers on time-sensitive pharmaceutical distribution, primarily specialty medications and radiopharmaceuticals for VA healthcare networks and the National Institutes of Health. Recent representative work includes a $139,008.58 sole-source delivery of Sirturo (bedaquiline) tablets to NIH Clinical Center in February 2026, where Cardinal Health 108 served as the manufacturer's exclusive U.S. distributor; a $2.16 million single-award Indefinite Delivery Contract with VA Veterans Integrated Service Network 20 for radiopharmaceuticals supporting nuclear medicine treatments, running through October 31, 2029, against which two delivery orders totaling $357 thousand have been issued; and routine purchase orders from VA VISN 2 and VISN 20 for oncology medications (Jelmyto, Korsuva), antivirals (Maribavir/Livtencity, Arcalyst), and emergency pharmaceutical supplies. Individual purchase orders range from approximately $3,700 to over $800,000, with place of performance split between Dublin, Ohio (primary distribution hub) and subordinate VA medical facilities across New York, Connecticut, Indiana, and other regions as named in specific orders.

The vendor's customer base is heavily concentrated in VA healthcare delivery, with 86% of awards funding Department of Veterans Affairs operations across nine distinct Veterans Integrated Service Networks. VA VISN 2 alone accounts for 27 awards (55% of total count) valued at $508 thousand combined potential value, dominated by small, routine pharmaceutical purchase orders with completion timelines of days to weeks reflecting emergency and urgent-supply procurement patterns. By dollar volume, however, VA VISN 20 leads with 4 awards carrying $2.7 million combined potential value, anchored by the radiopharmaceutical IDC. The National Institutes of Health Clinical Center places 5 awards worth $1.3 million, focused on specialized anti-tuberculosis and oncology agents (Sirturo, Floxuridine). The two rankings diverge sharply on concentration: VISN 2 dominates by award count but carries modest individual values, while VISN 20's radiopharmaceutical contract anchors most of the aggregate dollar exposure.

Cardinal Health 108 holds one parent vehicle: an Indefinite Delivery Contract (36C26025D0007) with VA VISN 20 valued at $2.16 million through October 2029, from which 2 delivery orders have been called against it. The vendor does not appear on GSA Schedules, GWACs, or agency-wide BPAs in the source material; all work is structured as direct purchase orders or task orders under single-award IDCs negotiated with specific VA networks and NIH.

Activity shows moderate recent growth: 3 awards in 2024, escalating to 16 in 2025 and 11 in 2026 year-to-date, driven by high-frequency small-dollar purchase orders from VA VISN 2. Four awards carrying combined potential value of $384 thousand face ultimate completion within the next twenty-four months, creating modest recompete exposure. The vendor operates entirely as a prime contractor (100% of awards); no sub-award footprint appears in the source.

Cardinal Health 108 competes in full-and-open procurement without set-aside category participation. The vendor's NAICS concentration runs to Pharmaceutical Preparation Manufacturing (43 awards) and Biological Product Manufacturing (1 award), with ancillary medical device and equipment orders (5 awards). PSC concentration mirrors this: Drugs and Biologicals (41 awards) dominate, with Medical and Surgical Instruments, Equipment, and Supplies (3 awards) and clinical services (2 awards) rounding out the portfolio. All awards carry firm fixed-price structures with no set-aside designations, indicating the vendor competes on capability and manufacturer-exclusivity positioning (particularly for branded specialty pharmaceuticals where Cardinal Health holds distributor agreements) rather than SBA-category preference.